|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
Surfactant replacement therapy for the treatment and prevention of neonatal respiratory distress syndrome (RDS) has been a major success story in respiratory care over the past decade. Animal-derived and synthetic surfactants are now available commercially throughout the world and there are several others in development. Surfactants are currently providing a miracle-like contribution towards dramatically improving the survival rate of critically ill infants with less than 30 weeks' gestation.
However, these advances may well be overshadowed by progressions in formulation technology that will make synthetic surfactants available for a number of other conditions. After the first few days from birth, adequate surfactant function is vitally important for optimal lung function. Surfactant dysfunction arising from a variety of mechanisms may contribute to a number of conditions. Surfactant therapy has been examined in a number of these with varying effects.
They include acute respiratory distress syndrome (ARDS) (1), respiratory syncytial virus bronchiolitis in infants (2), chronic bronchitis (3), chronic obstructive pulmonary disease (4), asthma (5,15), respiratory infections (6) and cystic fibrosis (7). Understanding the different roles of endogenous surfactant and the dysfunctions observed in these conditions must be a consideration when designing an effective therapy. In addition to opposing surface tension forces within the alveolus to maintain airway stability, surfactant has also been reported to promote mucociliary clearance (8), bind or neutralise aeroallergens, pollens, bacteria and other particulates (9,10), and oppose airway oedema (11).
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Line Clearance in Pharmaceutical Packaging & Manufacturing
5 February 2009, Manchester, UK
More info >>
|
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
|
